益气止血药对脾不统血证模型动物前列腺素的作用

采用复合因素的脾不统血证大鼠模型 ,以 6 酮 前列腺素F1α(6 酮 PGF1α)和血栓素B2(TXB2 )作为观测指标 ,对益气止血药对脾不统血证模型大鼠血浆和子宫前列腺素的影响进行了研究。结果 :大剂量组益气止血药能降低脾不统血证模型血浆和子宫的 6 酮 PGF1α及子宫 6 酮 PGF1α/TXB2 比值。说明 6 酮 PGF1α及 6 酮 PGF1α/TXB2 比值升高可能是脾不统血证的重要机理之一。     

Adverse events involving hallux metatarsophalangeal joint implants: Analysis of the United States Food and Drug Administration data from 2010 to 2018

BackgroundThe prevalence of osteoarthritis of the hallux metatarsophalangeal joint (MTPJ) is 1 in 40 people over the age of 50. Surgical treatment options for MTPJ arthritis include joint preservation, joint resurfacing, and arthrodesis. Hallux MTPJ implants have evolved over the past several decades, but are associated with various complications. The aim of this study was to examine the MAUDE database to determine reported adverse events for hallux MTPJ implants.Materials and methodsThe US Food and Drug Administration’s (FDA) Manufacturer and User Facility Device Experience (MAUDE) database was reviewed from 2010 to 2018 to review voluntary reported adverse event reports for approved implants within the United States. We recorded the type of adverse event and excluded duplicate reports and those extracted from already published literature.ResultsAmong 64 reported hallux MTPJ implant adverse events, the most common modes of adverse events were component loosening (34%), infection (14.1%), component fracture (9.4%), inflammation (9.4%), and allergic reaction (7.8%). Regarding implant type, Cartiva SCI had the highest percentage of adverse events (23.4%), followed by Arthrosurface ToeMotion (20.3%), Ascension MGT (12.5%), Arthrosurface HemiCAP® (10.9%), Futura primus (9.4%), and Osteomed Reflexion (6.3%). There was an increase in reported adverse events after 2016. The MAUDE database does not report the total incidence of implant insertion.ConclusionOur study of the MAUDE database demonstrated that component loosening and infection are the most common modes of adverse events for hallux MTPJ implants. Cartiva accounted for one-fourth of the implant-related adverse events during our study period, followed by ToeMotion, and Ascension MGT implants. Continued reporting of adverse events will improve our understanding on short and long-term complications of various hallux MTPJ implants.Level of evidenceLevel IV; Case Series from Large Database Analysis; Treatment Study.     

扑热息痛所致狗急性肝功能衰竭时血浆5-羟色胺变化及肝脏血流动力学改变的实验研究

目的;通过扑热息痛所致急性肝功能衰竭的动物模型,以期探讨门静脉,肝静脉,腹主动脉,下腔静脉血浆５－羟色胺浓度变化和肝脏血流动力学改变。方法：成年杂种狗１２只,在戊巴比妥钠静脉麻醉下,作上腹正中切口,从门静脉,肝静脉,腹主动脉,下腔静脉各采血２ｍｌ,作血浆５－羟色胺含量检测,作楔形肝组织活检,关腹。     

肾衰3号治疗难治性肾病综合征67例临床观察

[目的]探讨益气活血、解毒化浊法治疗难治性肾病综合征的效果。[方法]将97例难治性肾病综合征患者随机分为治疗组67例,对照组30例,对照组采用激素标准疗程治疗,治疗组在此基础上采用肾衰3号颗粒剂,主要成分为黄芪、人参、白术、葛根、淫羊藿、山茱萸等,观察近期、远期疗效,以及治疗前后24h尿蛋白定量(Uprot)、血肌酐(Scr)、血尿素氮(BUN)、血浆白蛋白(ALB)、胆固醇(TC)、甘油三酯(TG)的变化。[结果]治疗组近期疗效总有效率、远期疗效均显著优于对照组(P<0.05或P<0.01);治疗组Uprot、Scr、BUN、TG、TC水平明显降低,ALB水平升高与对照组比较P<0.05或P<0.01;同时副作用的发生明显降低,两组比较,差异极显著(P<0.01)。[结论]肾衰3号颗粒剂对难治性肾病综合征,具有良好的治疗作用。     

老年糖尿病合并感染的临床特征与治疗

目的:加强对老年糖尿病合并感染的诊断与治疗。方法:收集近4年来收治的老年糖尿病合并感染的病人进行总结。结果:老年糖尿病病人对血糖控制不理想,易造成多脏器损害。感染以G-菌为主,抗感染要采用降阶梯治疗。结论:老年糖尿病病人抵抗力差易造成感染,引发多脏器衰竭。尽早预测受损因素,合理使用抗生素,能延长老年糖尿病人的健康水平。     

酚妥拉明在60例婴幼儿肺炎心衰中的临床分析

目的：探讨肺炎合并心衰的治疗方法。方法：按日期将80例肺炎合并心衰患儿分为治疗组50例和对照组35例。活疗组在常规抗炎对症治疗基础上佐用酚妥拉明加阿拉明，对照组采用常规心衰之治疗．结果：治疗组痊愈率为90．0％，对照组为65．7％，差异有显著意义（P〈0．05）。结论：酚妥拉明和阿拉明治疗肺炎合并心衰疗效确切。     

医疗失效模式与效应分析在前列腺良性增生患者留置导尿管流程管理中的应用

[目的]探讨医疗失效模式与效应分析(HFMEA)在前列腺良性增生(BPH)患者留置导尿管流程管理中的应用效果.[方法]选取2019年1?6月(实施HFMEA管理前)本院老年病科收治的33例BPH留置导尿管患者作为对照组,选择2019年7?12月(实施HFMEA管理后)收治的35例BPH留置导尿管患者作为观察组.应用HF...     

失效模式与效应分析在低能X线术中放疗的应用

目的:探讨失效模式与效应分析(FMEA)在低能X线术中放疗(IORT)中的应用,分析其在IORT中的潜在风险,初步探讨FMEA优化IORT管理、减少潜在风险发生的可行性。方法:由IORT团队(1名放疗科医生、1名放疗科物理师、2名外科医生、2名护士)成立FMEA工作小组,应用FMEA方法开展系统风险评估。确立流程模块,...